IL234782A0 - Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics - Google Patents

Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics

Info

Publication number
IL234782A0
IL234782A0 IL234782A IL23478214A IL234782A0 IL 234782 A0 IL234782 A0 IL 234782A0 IL 234782 A IL234782 A IL 234782A IL 23478214 A IL23478214 A IL 23478214A IL 234782 A0 IL234782 A0 IL 234782A0
Authority
IL
Israel
Prior art keywords
diagnostics
lactamase
therapeutics
vivo imaging
bacterial beta
Prior art date
Application number
IL234782A
Other languages
Hebrew (he)
Inventor
D Cirillo Jeffrey
Rao Jianghong
Original Assignee
The Texas A& M Univ System
Univ Leland Stanford Junior
D Cirillo Jeffrey
Rao Jianghong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Texas A& M Univ System, Univ Leland Stanford Junior, D Cirillo Jeffrey, Rao Jianghong filed Critical The Texas A& M Univ System
Publication of IL234782A0 publication Critical patent/IL234782A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/986—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides (3.5.2), e.g. beta-lactamase (penicillinase, 3.5.2.6), creatinine amidohydrolase (creatininase, EC 3.5.2.10), N-methylhydantoinase (3.5.2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
IL234782A 2008-08-06 2014-09-22 Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics IL234782A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18811208P 2008-08-06 2008-08-06
US20360508P 2008-12-24 2008-12-24
PCT/US2009/004503 WO2010016911A2 (en) 2008-08-06 2009-08-06 Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics

Publications (1)

Publication Number Publication Date
IL234782A0 true IL234782A0 (en) 2014-11-30

Family

ID=41664121

Family Applications (2)

Application Number Title Priority Date Filing Date
IL211063A IL211063A0 (en) 2008-08-06 2011-02-03 Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics
IL234782A IL234782A0 (en) 2008-08-06 2014-09-22 Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL211063A IL211063A0 (en) 2008-08-06 2011-02-03 Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics

Country Status (15)

Country Link
US (1) US20100047172A1 (en)
EP (1) EP2318834A4 (en)
JP (1) JP5696947B2 (en)
KR (1) KR20110081147A (en)
CN (1) CN102369440B (en)
AU (1) AU2009280078B2 (en)
BR (1) BRPI0917478A8 (en)
CA (1) CA2732748A1 (en)
IL (2) IL211063A0 (en)
MX (1) MX2011001423A (en)
NZ (1) NZ591099A (en)
RU (1) RU2520661C2 (en)
SG (1) SG10201408809XA (en)
WO (1) WO2010016911A2 (en)
ZA (1) ZA201101151B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020240A1 (en) * 2008-08-06 2011-01-27 Cirillo Jeffrey D Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics
FR2956868B1 (en) * 2010-03-01 2014-01-10 Bio Rad Pasteur RAPID METHOD FOR DETECTION OF ENZYMES AND MICROORGANISMS
US9173966B2 (en) 2012-01-17 2015-11-03 The Regents Of The University Of California Luciferin derivatives from bicyclic reactants and aminothiol derivatives and methods of use thereof
CN103360385A (en) * 2012-04-06 2013-10-23 上海交通大学医学院附属第三人民医院 Compound and medicament for treating MRSA (Methicillin-resistant Staphylococcus Aureus) infection
CN103512871B (en) * 2012-06-28 2017-04-12 上海百可生物科技股份有限公司 Bacterial drug resistance fluorescence detection method and diagnostic kit thereof
CN103509083B (en) * 2012-06-28 2016-06-08 王郁生 A kind of wide spectrum beta-lactamase fluorogenic substrate and its preparation method and application
KR20180010177A (en) * 2015-01-22 2018-01-30 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Protease-activated contrast agent for in vivo imaging
CN104714006B (en) * 2015-02-04 2017-10-20 国家纳米科学中心 A kind of method of beta lactamase in detection dairy produce
JP7064732B2 (en) * 2016-10-27 2022-05-11 ネクスジェン株式会社 How to identify genes that are specifically expressed using optimized labels
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN111458313A (en) * 2020-04-07 2020-07-28 上海交通大学医学院附属仁济医院 Antibacterial drug sensitivity test detection method based on fluorescent D-type amino acid metabolism marker
CN111638197B (en) * 2020-05-25 2022-10-21 南京工业大学 Probe for detecting beta-lactamase and application thereof in fluorescence detection of drug-resistant bacteria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916433A1 (en) * 1979-04-24 1980-11-13 Hoechst Ag CHROMOPHORE CEPHALOSPORINE AND METHOD FOR THE PRODUCTION THEREOF
US5338843A (en) * 1992-01-30 1994-08-16 Becton, Dickinson And Company Fluorogenic and chromogenic β-lactamase substrates
RU2117045C1 (en) * 1992-03-20 1998-08-10 Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии Method of assay of mycobacterial beta-lactamase activity
US5741657A (en) * 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use

Also Published As

Publication number Publication date
US20100047172A1 (en) 2010-02-25
NZ591099A (en) 2013-10-25
IL211063A0 (en) 2011-04-28
SG10201408809XA (en) 2015-03-30
EP2318834A2 (en) 2011-05-11
WO2010016911A2 (en) 2010-02-11
AU2009280078A1 (en) 2010-02-11
WO2010016911A3 (en) 2010-06-24
JP5696947B2 (en) 2015-04-08
RU2011108545A (en) 2012-09-20
AU2009280078B2 (en) 2015-07-02
ZA201101151B (en) 2012-08-29
JP2011530285A (en) 2011-12-22
RU2520661C2 (en) 2014-06-27
CA2732748A1 (en) 2010-02-11
EP2318834A4 (en) 2013-06-19
CN102369440B (en) 2016-02-17
KR20110081147A (en) 2011-07-13
BRPI0917478A8 (en) 2017-05-23
CN102369440A (en) 2012-03-07
MX2011001423A (en) 2011-04-27
BRPI0917478A2 (en) 2015-12-01

Similar Documents

Publication Publication Date Title
IL234782A0 (en) Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics
ZA201300050B (en) Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging,diagnostics and therapeutics
IL290501A (en) Systems and methods for ex vivo lung care
HK1255503A1 (en) Methods for the diagnosis of bacterial vaginosis
EP2282672A4 (en) Systems and methods for imaging changes in tissue
EP2344042A4 (en) Methods for acquisition and display in ultrasound imaging
EP2244712A4 (en) In vivo studies of crystalline forms of meloxicam
EP2324337A4 (en) Front end circuitry for imaging systems and methods of use
EP2155065A4 (en) Methods for in vivo imaging of cells
EP2413794A4 (en) Support component for use in imaging by magnetic resonance and x-ray
EP2471556A4 (en) Contrast agent for photoacoustic imaging and photoacoustic imaging method utilizing same
GB0817650D0 (en) Improvements in the field of imaging
EP2188632A4 (en) Bacterial vaginosis apparatus and diagnostic methods
EP2358868A4 (en) In vitro human b lymphopoiesis culture system
EP2171478A4 (en) In vivo imaging of sulfotransferases
GB0815846D0 (en) diagnosis, prognosis and imaging of disease
HK1170542A1 (en) Methods and compositions for diagnostics use in cancer patients
EP2257316A4 (en) Contrast agents, methods for preparing contrast agents, and methods of imaging
IL199618A0 (en) Novel antibodies and their use in diagnostic methods
EP2410052A4 (en) In vitro method for the detection of candida glabrata, diagnostic kit and use thereof
EP2350001A4 (en) Novel benzylidene-indolinone and their medical and diagnostic uses
EP2321320A4 (en) Novel compounds and their uses in diagnosis
GB0917612D0 (en) In vivo imaging agents
WO2012040108A3 (en) Multivalent fluorescent probes
GB201012209D0 (en) In vivo imaging agent